CASCADE BIOTECHNOLOGY - Key Persons

Job Titles:

• Chief Scientific Officer, Cue Biopharma
• Senior Vice President and Chief Scientific Officer at Cue Bioppharma

Anish Suri, Ph.D. is the Senior Vice President and Chief Scientific Officer at Cue Bioppharma. Dr. Suri, recently served as Senior Director of Janssen Immunosciences in Belgium. Dr. Suri is an immunologist with more than 20 years of experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation. Prior to joining Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical Companies, most recently as Senior Director at Janssen Immunosciences. Prior to Janssen, he was responsible for providing strategic guidance to immuno-oncology and immunology drug discovery programs at Bristol-Myers Squibb Pharmaceutical Research Institute. Prior to his work in the pharmaceutical industry, Dr. Suri was Assistant Professor of Pathology and Immunology at Washington University School of Medicine. He received his Ph.D. in immunology from Washington University.

Job Titles:

• Chief Executive Officer
• Management

Daniel E. Benjamin Ph.D. is the Chief Executive Officer (CEO) of our company. With his extensive knowledge and experience, he leads the organization in setting strategic goals and implementing effective business strategies. He oversees the overall operations of the company, including financial performance, resource allocation, and risk management. Under his leadership, the company has achieved significant growth and success. Dr Benjamin's graduate studies began in Prof. Harbans Lal's Lab in the department of pharmacology at University of North Texas Health Sciences Center. The department focused on Alzheimer's disease and cognitive. Harbans Lal was one of the first investigators to test for a role of autoimmunity in age-related cognitive decline. This training occurred at the dawn of Alzheimer's research, and taught that extreme risk can result in substantial reward. In addition to the core knowledge of pharmacodynamics and pharmacokinetics, Dr. Benjamin learned neuroanatomy and neurocircuitry in depth, as well as the logical basis and scientific precedents that allowed for solid functional conclusions on the neuroanatomical basis of physiology. Dr. Benjamin was the recipient of a competitive award from American Cyanamid Corporation to study the neuropharmacology and molecular biology of serotonin receptors. At Cascade, we are currently studying the role of complement in Renal disease, Schizophrenia, and Alzheimer's disease and developing a gene therapy technology to deliver our complement depleting protein.

Job Titles:

• Chief Biotechnology Officer

Job Titles:

• Professor of OphthalmologyMedical University of South Carolina

Dr. Bärbel Rohrer is Professor of Ophthalmology and the SmartState Endowed Chair in Gene and Pharmaceutical Treatment of Retinal Degenerative Diseases at MUSC, a VA Research Scientist, and an academic and innovative leader in diseases of the retina. She holds three U.S. and five international patents, with an additional 22 applications pending. Her IP contributed to the foundation for three start-up companies, one of which she co-founded. A major pharmaceutical company acquired one, the other two companies are continuing clinical development of her therapies. She has published >70 manuscripts; received 37 peer-reviewed grants; serves as editor/reviewer for many journals; and mentored 50+ trainees. She is a National Academy of Inventors (NAI) Fellow, Foundation Fighting Blindness Scientific Advisory Board member and member of multiple professional societies, including the Association for Research in Vision and Ophthalmology and the Society for Neuroscience. Dr. Rohrer's educational background includes a Neuroscience Diploma from the University of Tübingen, a Neuroscience PhD from the University of Calgary, and postdoctoral training at UCSF.

Job Titles:

• Consultant to Business Development
• Management

Duncan P. Taylor, Ph.D., recently retired as Senior Director, Business Development, for SK Life Science Inc. He joined that company in 2008 and was responsible for the identification and evaluation of the strategic and financial prospects of new market opportunities and their pursuit. His 30+-year career in the pharmaceutical industry encompassed roles as Senior Director of Strategic Intelligence in Business Development with Biovail Pharmaceuticals for 3 years (now part of Valeant Pharmaceuticals), Director of Strategic Research Assessment for the Pharmacia Corporation (previously Pharmacia & Upjohn and now part of Pfizer) for 7 years, Director of Pharmacology for Symphony Pharmaceuticals, a privately-held start-up pharmaceutical research company, Senior Research Fellow for Bristol-Myers Squibb in Central Nervous System Biological Discovery for 15 years, and as an independent consultant. His efforts during those tenures have succeeded in the successful in-licensing of Axert® (almotriptan), a treatment for migraine headaches, for North America; the discovery, approval, and marketing of Serzone® (nefazodone), a treatment for major depressive disorder; and significant contributions to the development, approval, and marketing of BuSpar® (buspirone), for generalized anxiety disorder, Stadol® NS (transnasal butorphanol), for the relief of moderate to severe pain, and Desyrel® (trazodone), for the treatment of depression. He has authored or co-authored over 50 monographs and published articles, 20 book chapters, and over 90 abstracts in the scientific literature; he and his associates have issued over 250 scientific, technical, and competitive intelligence internal reports; and he is the inventor or co-inventor on 21 issued patents and 28 published pending patent applications. Dr. Taylor received his B.S. in chemistry from the California Institute of Technology, his Ph.D. in biochemistry from Oregon State University, and received a National Research Service Award from the National Institute on Drug Abuse for his work at the National Institute for Mental Health in Bethesda, MD. He has been elected to Sigma Xi and Phi Lambda Upsilon (research and chemistry honorary societies), is a Fellow of the American Institute of Chemists, and has been listed in numerous biographical listings since 1982. He is a past member of the Licensing Executives Society as well as a number other scientific and medical professional societies. Dr. Taylor lives in Flemington, NJ, with his wife of 42 years.

Job Titles:

• Chief Operating Officer, V.P. Business Development